Eli Lilly announces Ajax Therapeutics acquisition for up to $2.3B
NewsBytes | April 28, 2026 12:40 AM CST
AJ1-11095 shows early promise
The heart of this deal is AJ1-11095, an oral drug from Ajax that is still in early testing but shows promise for patients who have not had much luck with other treatments.
Eli Lilly wants to share clinical results by 2026 and speed things up from there.
Lilly says they are excited about bringing something important to people fighting blood cancer.
READ NEXT
-
Child dies after cobra bite in Kerala
-
Karnataka orders inspection of hospital buildings after deadly Bengaluru wall collapse
-
Lucknow Student Achieves Top Marks in ICSE Class 10 Results
-
Akhilesh Yadav Criticizes BJP Government's Alleged Misuse of Power
-
AMU Nigerian Student's '3 Idiots'-Style Hindi Speech Goes Viral - WATCH
